Celmatix Nominates First Lead Compound in Oral Fertility Drug Program
Celmatix Inc. has announced the nomination of a lead compound in its oral Follicle Stimulating Hormone receptor (FSHR) agonist drug development program. This represents a major milestone, with the potential to transform fertility treatments for both men and women. The announcement coincides with the annual meeting of the American Society for Reproductive Medicine (ASRM), currently underway in Denver, Colorado.